Overview

This trial is active, not recruiting.

Condition chronic migraine, headaches
Treatment onabotulinumtoxina
Sponsor Allergan
Start date November 2012
End date June 2014
Trial size 33 participants
Trial identifier NCT01749410, GMA-BTX-CM-12-491

Summary

This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine Headache patients who have received a minimum of 7 treatment cycles.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case-only
Time perspective retrospective
Arm
Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective medical record review.
onabotulinumtoxina botulinum toxin Type A
Previous treatment with onabotulinumtoxinA for Chronic Migraine.

Primary Outcomes

Measure
Number of Headache Days
time frame: Up to 2 years

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria: - 15 or more headache days over a 30 day period - A minimum of 7 treatment cycles with onabotulinumtoxinA Exclusion Criteria: - Any treatment cycle dose of onabotulinumtoxinA greater than 200 units

Trial information was received from ClinicalTrials.gov and was last updated in April 2014.
Information provided to ClinicalTrials.gov by Allergan.